COMPARATIVE EFFICACY AND SAFETY OF TOFACITINIB AND BIOLOGICS AS INDUCTION THERAPY FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引：0
|
作者：
Rubin, D. T. [1 ]
Ashaye, A. O. [2 ]
Zhang, Y. [3 ]
Xu, Y. [2 ]
Fahrbach, K. [2 ]
Chen, L. A. [4 ]
Manuchehri, A. [5 ]
Kayhan, C. [6 ]
Woolcott, J. C. [7 ]
Cappelleri, J. C. [8 ]
Healey, P. [8 ]
机构：
[1] Univ Chicago Med, Chicago, IL USA
[2] Evidera Inc, Waltham, MA USA
[3] Evidera, London, England
[4] NYU Langone Med Ctr, New York, NY USA
[5] Pfizer Ltd, Tadworth, England
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer Canada Inc, Kirkland, PQ, Canada
[8] Pfizer Inc, Groton, CT 06340 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI4
引用
收藏
页码：A180 / A180
页数：1
相关论文
共 50 条
  • [1] Efficacy of Tofacitinib and Biologics as Induction and Maintenance Therapy for Moderately-to-Severely Active Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
    Rubin, David T.
    Ashaye, Ajibade
    Zhang, Younan
    Fahrbach, Kyle
    Freitag, Andreas
    Kayhan, Cem
    Lohan, Christoph
    Cappelleri, Joseph C.
    DiBonaventura, Marco
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S402 - S403
  • [2] Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis
    Dignass, Axel
    Ainsworth, Claire
    Hartz, Susanne
    Dunnewind, Niels
    Redondo, Isabel
    Sapin, Christophe
    Kroep, Sonja
    Halfpenny, Nicholas
    Arca, Emanuele
    Hoque, Sami
    ADVANCES IN THERAPY, 2024, 41 (12) : 4446 - 4462
  • [3] Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
    Vickers, Adrian D.
    Ainsworth, Claire
    Mody, Reema
    Bergman, Annika
    Ling, Caroline S.
    Medjedovic, Jasmina
    Smyth, Michael
    PLOS ONE, 2016, 11 (10):
  • [4] A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY AND SAFETY OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    LeReun, C.
    Wright, E.
    Lohan, C.
    Diamantopoulos, A.
    Bohm, N.
    Sawyer, L.
    VALUE IN HEALTH, 2019, 22 : S616 - S616
  • [5] Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis (UC): A Systematic Review and Network Meta-Analysis
    Vickers, Adrian D.
    Mody, Reema
    Bergman, Annika
    Ling, Caroline S.
    Ainsworth, Claire
    Medjedovic, Jasmina
    Smyth, Michael D.
    GASTROENTEROLOGY, 2015, 148 (04) : S272 - S272
  • [6] Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): A systematic review and network meta-analysis
    Vickers, A. D.
    Mody, R. R.
    Bergman, A.
    Ling, C. S.
    Ainsworth, C.
    Medjedovic, J.
    Smyth, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S357 - S358
  • [7] Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
    Lohan, Christoph
    Diamantopoulos, Alex
    LeReun, Corinne
    Wright, Emily
    Bohm, Natalie
    Sawyer, Laura Marie
    BMJ OPEN GASTROENTEROLOGY, 2019, 6 (01):
  • [8] Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis
    Jairath, Vipul
    Raine, Tim
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025,
  • [9] Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis
    Danese, Silvio
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Lucenteforte, Ersilia
    Virgili, Gianni
    Moja, Lorenzo
    Bonovas, Stefanos
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (10) : 704 - +
  • [10] Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
    Xinlin Chen
    Jiangtao Hou
    Yujie Yuan
    Chaoyuan Huang
    Tianwen Liu
    Chuanwei Mo
    Haiwen Li
    Bin Chen
    Qian Xu
    Zhengkun Hou
    Weiling He
    Fengbin Liu
    BioDrugs, 2016, 30 : 207 - 217
12345